COMMENTARY

• Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
  June 15, 2015

• Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
  May 26, 2015

• 1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
  May 8, 2015

• Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
  April 27, 2015

• Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
  April 17, 2015

• Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
  April 7, 2015

• Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
  March 30, 2015

• SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
  March 17, 2015

• Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
  March 16, 2015

• Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
  March 6, 2015

• As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
  February 16, 2015

• Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
  February 2, 2015

• Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
  January 26, 2015

• Have AGs Finally Become a Good Option to Counter Generics?
  January 19, 2015

• Will Legal Regulation Propel or Stymie Clinical Research? “Risk-Based” Approach Holds Key
  January 13, 2015

• Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
  December 22, 2014

• April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
  December 15, 2014

• Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
  December 5, 2014

• Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy
  November 25, 2014

• Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs
  November 18, 2014

ページ